NEW YORK, NY / ACCESSWIRE / February 26, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
AZN Shareholders Click Here: https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=13163&wire=1
EH Shareholders Click Here: https://www.zlk.com/pslra-1/ehang-holdings-limited-loss-submission-form?prid=13163&wire=1
EBIX Shareholders Click Here: https://www.zlk.com/pslra-1/ebix-inc-loss-submission-form?prid=13163&wire=1
* ADDITIONAL INFORMATION BELOW *
Astrazeneca Plc (NYSE:AZN)
AZN Lawsuit on behalf of: investors who purchased May 21, 2020 - November 20, 2020
Lead Plaintiff Deadline : March 29, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=13163&wire=1
According to the filed complaint, during the class period, Astrazeneca Plc made materially false and/or misleading statements and/or failed to disclose that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.
Ehang Holdings Limited (NASDAQ:EH)
EH Lawsuit on behalf of: investors who purchased December 12, 2019 - February 16, 2021
Lead Plaintiff Deadline : April 19, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ehang-holdings-limited-loss-submission-form?prid=13163&wire=1
According to the filed complaint, during the class period, Ehang Holdings Limited made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's purported regulatory approvals in Europe and North American for its EH216 were for use as a drone, and not for carrying passengers; (ii) its relationship with its purported primary customer is a sham; (iii) EHang
has only collected on a fraction of its reported sales since its ADS began trading on NASDAQ in December 2019; (iv) the Company's manufacturing facilities were practically empty and lacked evidence of advanced manufacturing equipment or employees; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Ebix, Inc. (NASDAQ:EBIX)
EBIX Lawsuit on behalf of: investors who purchased November 9, 2020 - February 19, 2021
Lead Plaintiff Deadline : April 23, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ebix-inc-loss-submission-form?prid=13163&wire=1
According to the filed complaint, during the class period, Ebix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that there was insufficient audit evidence to determine the business purpose of certain significant unusual transactions in Ebix's gift card business in India during the fourth quarter of 2020; (2) that there was a material weakness in Company's internal controls over the gift or prepaid revenue transaction cycle; and (3) that the Company's independent auditor was reasonably likely to resign over disagreements with Ebix regarding $30 million that had been transferred into a commingled trust account of Ebix's outside legal counsel; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP